Increased risk of type 2 diabetes in Alzheimer disease.

By J. Janson, Thomas Laedtke, Joseph E. Parisi, P. O'brien, Ronald C. Petersen, P. Butler. Diabetes, 2004

951 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/b61807df9029fa3e1bfbee64e55fd39b586b25f2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Network-based in silico drug efficacy screening (2016, neutral): “T2D and AD are known to share a common pathology and exhibit increased co-morbidity 29,30 .”
Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, background): “Furthermore, metabolic syndrome characterized by insulin resistance has also been demonstrated to have increased risk of AD (Ferreira et al., 2010; Garcia-Lara et al., 2010; Janson et al., 2004).”
Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. (2012, positive): “A more accurate term, in our view, is insulin-resistant brain state (12), a neural variant of the insulin resistance syndrome (154) that was previously identified as a feature of several disorders, most notably T2D (1,2), the metabolic syndrome (155), and AD itself (12, 21, 34, 156).”
Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. (2008, background): “In this regard it is of interest that hIAPP and A P share close structural properties and that the prevalence of Alzheimer’s disease is increased in people with T2DM (107).”
The Gut Microbiota and Alzheimer’s Disease (2017, positive): “Interestingly, it has been estimated that up to 81% of AD patients have T2DM or impairment of glucose metabolism [131].”
Inflammation as a central mechanism in Alzheimer's disease (2018, neutral): “[245] Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC.”
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. (2012, positive): “Recent studies have shown that type 2 diabetes increases the risk of AD (51), and a newly recognized form of brain insulin resistance has been connected to AD (2, 3).”
Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease (2018, background): “Moreover, the incidence of type 2 diabetes is increased in AD patients (Janson et al., 2004), and it was recently shown that tau protein is involved in the control of brain insulin signaling (Marciniak et al.”
Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. (2005, positive): “Upon review of the Mayo Clinic Alzheimer disease patient registry, the authors found that islet amyloid was increased in Alzheimer compared to control subjects and that the slope of the increase of fasting plasma glucose concentration was greater in Alzheimer versus control individuals (Janson et al”